Welcome to the future of biopharmaceutical R&D and Manufacturing. Our advanced metabolic-strain engineering and purification platforms enable revolutionary efficiencies in biopharmaceutical discovery and manufacturing.

Accelerate the drug discovery process using AbSci’s all-in-one protein expression platform, SoluPro™. The optimization process enables rapid expression of soluble, complex proteins in high yields, and puts the focus on screening lead candidates instead of producing them.

SoluPro™, AbSci’s next-generation E. coli expression platform, generates diverse protein products at unparalleled yields compared to current manufacturing processes. Our technologies decrease COGs, reduce production times, and significantly increase plant capacity.

SoluPro™, our all-in-one protein expression platform, produces complex proteins ranging from full-length antibodies to insulin using the simplest, best studied, and least expensive organism, E. coli.

AbSci Advantages

Next-generation E. coli production cell line produces soluble, disufide bonded, active protein without refolding

Gene to GMP drug substance in 6-9 months due to rapid cell line development and elimination of viral clearance

“First-of-its-kind” workflow provides partners an optimized cell line in 10-12 weeks

Up to 75% reduction in drug substance costs due to high titers and reduced number of production runs

Ultra-High Yield Streamlined Protein Production

OUR TECHNOLOGY

Two key innovations form the foundation of the SoluPro™ protein expression platform: a genetically engineered semi-oxidizing cytoplasm and a dual inducible promoter system that enables precise tuning of protein production rates. These attributes enable soluble production of a range of complex, disulfide bonded proteins with short production cycles. Soluble production and the ease of manipulation of E. coli enable AbSci to deploy a high-throughput workflow to rapidly screen large quantities of genetic diversity.

A suite of proprietary assays that optimize for protein titer, function, and quality have been developed to screen diversity numbering in the millions of strains. When combined, these assays form the foundation of a high-throughput workflow that rapidly identifies high-titer producing strains. SoluPro is a unique solution for production of antibody and next-generation protein therapeutics such as Fabs, Fc-fusions, and multispecifics at high-titers in excess of 4 g/L.

Traditionally, protein expression in E. coli is achieved either through cytoplasmic production as inclusion bodies or through secretion into the periplasmic space. SoluPro™ expresses soluble, disulfide linked proteins through production in a semi-oxidized cytoplasm.

AbSci takes advantage of the simplicity of E. coli to assemble and screen large pools of genetic diversity in parallel. Using high-throughput assays and workflows, the ideal production strain can be identified in 3 months or less. Rapid optimization of a high-titer producing strains enables pharmaceutical and biotech partners to go from gene to GMP drug substance in less than 9 months and eliminates the need for viral clearance, which results in dramatic time savings compared to CHO.

At scale, SoluPro™ creates breakthrough efficiencies in biomanufacturing, reducing the number of production campaigns or scale of bioreactor required to produce sufficient drug substance. By returning biomanufacturing to its E. coli roots, AbSci aims to replace CHO and other mammalian expression platforms as the expression host of choice.

AbSci’s high throughput workflow generates cell lines that produce folded, active protein product in as little as 3 months.

AbSci’s high throughput workflow generates cell lines that produce folded, active protein product in as little as 3 months.

PARTNERSHIPS

Molecules

Partners

PARTNERSHIPS

Absci collaborates with leading pharmaceutical companies to enable step-changes in productivity to their bio-pharmaceutical R&D and manufacturing.

AbSci is supported by a syndicate of experienced investors:

“People in the industry have been talking about folding protein in E. coli for years. Before it was just theoretically possible, but the SoluPro™ Platform now makes it technically possible to fold full-length antibodies and proteins in E. coli.”

Fred Larimore, PhD, Former Research Fellow at Eli Lilly

ABOUT US

We are a fearless, intellectually energetic team of scientists continually defining the future of drug discovery and manufacturing for the biopharmaceutical industry.

AbSci scientists are iconoclasts, defying established industry practices, resolute in a shared conviction that the status quo for biomanufacturing is obsolete. We attract passionate, imaginative and accomplished scientists who are risk takers, keen to experiment, collaborate and create extraordinary drug discovery and manufacturing tools to disrupt and transform how life-changing biologics are made.

Our Scientific Advisory Board and Board of Directors are comprised of world-class scientists who bring decades of experience leading and igniting the biotech industry in all facets of drug discovery and biomanufacturing.

 

Zach Jonasson, Ph.D.

Chairman, Managing Partner PVP

V. Bryan Lawlis, Ph.D.

Independent Consultant

Sean McClain

Founder & CEO

Dan Gold, Ph.D.

VP Process Sciences, BioMarin

Phil Barish, Ph.D.

VP of Operations and R&D

Gustavo Mahler, Ph.D.

CEO, AGC Biologics

Sean McClain

Founder & CEO

Suzanne Sprunger, Ph.D., J.D.

Chief Intellectual Property Officer

Phil Barish, Ph.D.

VP, Research and Operations

Penelope

Chief Morale Officer

Shelley Klassen, CPA, CMA

Chief Financial Officer

Dan Hunt

Licensing and Transaction Counsel

V. Bryan Lawlis, Ph.D.

Chairman, Independent Consultant

Bill Bennett, Ph.D.

Principal, Bioscope Associates

Dan Gold, Ph.D.

VP Process Sciences, BioMarin

Fred Larimore, Ph.D.

Principal, Sierra Vista Biotech

Alan Herman, Ph.D.

CSO, Coherus

Andrew J.S. Jones, D. Phil.

Independent Consultant

“AbSci reminds me of Genentech in the early 80’s, they’ve taken on some really hard problems to explain and there’s no fear around solving these key industry issues.”

V. Bryan Lawlis, PhD, Former VP of Process Science at Genentech

CAREERS

Join the Team | Change an Industry

At AbSci, we defy established protein expression conventions and continually invent new technologies and approaches which introduce efficiencies and cost savings to the biotech industry. We are looking for original thinkers, accomplished and energetic scientists who have the imagination to join us and re-define what’s possible.

NEWS / UPDATES / PRESS
10 Life Science Innovators Under 40 to Watch

10 Life Science Innovators Under 40 to Watch

There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators. Culling from a variety of lists that...

read more

AbSci to Attend BPI-West 2019

If you have an interest in learning more about AbSci's expression platform, SoluPro, or would like to hear about AbSci's novel 12-week cell line optimization workflow, reach out to Kole Krieger to schedule some time to meet. kkrieger@abscibio.com  

read more

101 E 6th Street, Suite 300, Vancouver, WA 98660 Tel. 360-949-1041
Terms / Privacy / Cookie Policy / © Copyright 2019 Absci LLC

Absci Vancouver

Absci 101 E 6th Street, Suite 300, Vancouver, WA 98660